1
|
Yeo TP: Demographics, epidemiology, and
inheritance of pancreatic ductal adenocarcinoma. Semin Oncol.
42:8–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Krška Z, Šváb J, Hoskovec D and Ulrych J:
Pancreatic cancer diagnostics and treatment - current state. Prague
Med Rep. 116:253–267. 2015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Fang EF and Ng TB: A trypsin inhibitor
from rambutan seeds with antitumor, anti-HIV-1 reverse
transcriptase, and nitric oxide-inducing properties. Appl Biochem
Biotechnol. 175:3828–3839. 2015. View Article : Google Scholar : PubMed/NCBI
|
4
|
Li PG, Mu TH and Deng L: Anticancer
effects of sweet potato protein on human colorectal cancer cells.
World J Gastroenterol. 19:3300–3308. 2013. View Article : Google Scholar : PubMed/NCBI
|
5
|
Yao J and Qian C: Sporamin induce
apoptosis in human tongue carcinoma cells by down-regulating
Akt/GSK-3 signaling. Fundam Clin Pharmacol. 25:229–236. 2011.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Kolch W: Meaningful relationships: The
regulation of the Ras/Raf/MEK/ERK pathway by protein interactions.
Biochem J 351 Pt. 2:289–305. 2000. View Article : Google Scholar
|
7
|
Peti W and Page R: Molecular basis of MAP
kinase regulation. Protein Sci. 22:1698–1710. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Johnson GL and Lapadat R:
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and
p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
|
9
|
Furukawa T: Impacts of activation of the
mitogen-activated protein kinase pathway in pancreatic cancer.
Front Oncol. 5:232015. View Article : Google Scholar : PubMed/NCBI
|
10
|
Olechowska-Jarząb A, Ptak-Belowska A and
Brzozowski T: Terapeutic importance of apoptosis pathways in
pancreatic cancer. Folia Med Cracov. 56:61–70. 2016.
|
11
|
Gong W, Song Q, Lu X, Gong W, Zhao J, Min
P and Yi X: Paclitaxel induced B7-H1 expression in cancer cells via
the MAPK pathway. J Chemother. 23:295–299. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Xu X, Tu L, Jiang W, Feng W, Zhao CX and
Wang DW: Bradykinin prevents the apoptosis of NIT-1 cells induced
by TNF-α via the PI3K/Akt and MAPK signaling pathways. Int J Mol
Med. 29:891–898. 2012.PubMed/NCBI
|
13
|
Grossi V, Peserico A, Tezil T and Simone
C: P38α MAPK pathway: A key factor in colorectal cancer therapy and
chemoresistance. World J Gastroenterol. 20:9744–9758. 2014.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Tan W, Yu HG and Luo HS: Inhibition of the
p38 MAPK pathway sensitizes human gastric cells to doxorubicin
treatment in vitro and in vivo. Mol Med Rep. 10:3275–3281. 2014.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Yao J, Qian CJ, Ye B, Zhang X and Liang Y:
ERK inhibition enhances TSA-induced gastric cancer cell apoptosis
via NF-κB-dependent and Notch-independent mechanism. Life Sci.
91:186–193. 2012. View Article : Google Scholar : PubMed/NCBI
|
16
|
Schweyer S, Soruri A, Meschter O, Heintze
A, Zschunke F, Miosge N, Thelen P, Schlott T, Radzun HJ and Fayyazi
A: Cisplatin-induced apoptosis in human malignant testicular germ
cell lines depends on MEK/ERK activation. Br J Cancer. 91:589–598.
2004. View Article : Google Scholar : PubMed/NCBI
|
17
|
Xia Z, Dickens M, Raingeaud J, Davis RJ
and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases
on apoptosis. Science. 270:1326–1331. 1995. View Article : Google Scholar : PubMed/NCBI
|
18
|
Huang P, Han J and Hui L: MAPK signaling
in inflammation-associated cancer development. Protein Cell.
1:218–226. 2010. View Article : Google Scholar : PubMed/NCBI
|
19
|
Haagenson KK and Wu GS: The role of MAP
kinases and MAP kinase phosphatase-1 in resistance to breast cancer
treatment. Cancer Metastasis Rev. 29:143–149. 2010. View Article : Google Scholar : PubMed/NCBI
|
20
|
Liu L, Zhang H, Sun L, Gao Y, Jin H, Liang
S, Wang Y, Dong M, Shi Y, Li Z and Fan D: ERK/MAPK activation
involves hypoxia-induced MGr1-Ag/37LRP expression and contributes
to apoptosis resistance in gastric cancer. Int J Cancer.
127:820–829. 2010.PubMed/NCBI
|
21
|
Zheng C, Jiao X, Jiang Y and Sun S: ERK1/2
activity contributes to gemcitabine resistance in pancreatic cancer
cells. J Int Med Res. 41:300–306. 2013. View Article : Google Scholar : PubMed/NCBI
|